登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，3月11日，Implications of COVID-19 for patients with pre-existing digestive diseases》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-12

  • Implications of COVID-19 for patients with pre-existing digestive diseases

    Ren Mao

    Jie Liang

    Jun Shen

    Subrata Ghosh

    Liang-Ru Zhu

    Hong Yang

    et al.

    Show all authors

    Published:March 11, 2020DOI:https://doi.org/10.1016/S2468-1253(20)30076-5

    The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in China, in December, 2019, now affects the whole world. As of March 8, 2020, more than 105?000 laboratory-confirmed cases and more than 3500 deaths in over 100 countries had been reported.

  • 原文来源：https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30076-5/fulltext
25浏览量
原文链接
相关报告

  • 《LANCET，3月23日，COVID-19 and medical education》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-24
    • COVID-19 and medical education Hanad Ahmed Mohammed Allaf Hussein Elghazaly Published:March 23, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30226-7 The coronavirus disease 2019 (COVID-19) outbreak has rapidly transitioned into a worldwide pandemic. This development has had serious implications for public institutions and raises particular questions for medical schools. Frequent rotations between departments and hospitals make medical students potential vectors for COVID-19. Equally, as trainee doctors we stand to learn a tremendous amount and can contribute to the care of patients, particularly if the UK General Medical Council triggers article 18a of the Medical Student Act (1983).
    124浏览量
    原文链接

  • 《CELL，4月30日，Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-03
    • Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes Lihua Zhu 28Zhi-Gang She 28Xu Cheng 28Jiao GuoBing-Hong ZhangHongliang Li 29 Published:April 30, 2020DOI:https://doi.org/10.1016/j.cmet.2020.04.021 Type 2 diabetes (T2D) is a major comorbidity of COVID-19. However, the impact of blood glucose (BG) control on the degree of required medical interventions and on mortality in patients with COVID-19 and T2D remains uncertain. Thus, we performed a retrospective, multi-centered study of 7,337 cases of COVID-19 in Hubei Province, China, among which 952 had pre-existing T2D. We found that subjects with T2D required more medical interventions and had a significantly higher mortality (7.8% versus 2.7%; adjusted hazard ratio [HR], 1.49) and multiple organ injury than the non-diabetic individuals. Further, we found that well-controlled BG (glycemic variability within 3.9 to 10.0 mmol/L) was associated with markedly lower mortality compared to individuals with poorly controlled BG (upper limit of glycemic variability exceeding 10.0 mmol/L) (adjusted HR, 0.14) during hospitalization. These findings provide clinical evidence correlating improved glycemic control with better outcomes in patients with COVID-19 and pre-existing T2D.
    41浏览量
    原文链接